EXTON, Pa., Sept. 21, 2018 /PRNewswire/ -- Almirall, S.A. (ALM) announced today the finalization of their acquisition of products from Allergan's Medical Dermatology unit in the United States: Aczone® (dapsone), Tazorac® (tazarotene), Azelex® (azelaic acid) and Cordran® Tape (flurandrenolide). In addition, sarecycline, a New Chemical Entity (NCE) currently under FDA review for approval in the treatment of acne is part of the transaction.
Spain’s Almirall has acquired Allergan’s US dermatology portfolio in a deal worth up to $650 million. This includes an upfront cash payment of $550 million and a potential earn-out of up to $100 million payable in 2022 based on the performance of the portfolio.
Teligent's Generic Flurandrenolide Receives Approval In US
Teligent Pharma`s Generic Flurandrenolide approved in US to treat inflammation and itching
Actavis Laboratories, Ongoing Class III recall of Flurandrenolide Tape, USP, 4 mcg per sq cm, Rx Only. Distributed By: Actavis Pharma, Inc., Parsippany, NJ 07054, Manufactured By: 3M Company, St. Paul, MN, 55144. Labeled as A) Cordran Tape, Small Rolls, 24 in x 3 in, NDC: 52544-044-24, B) Cordran Tape, Large Rolls, 80 in x 3 in, NDC: 52544-044-80, C) Haelan Tape (Fludroxycortide), Bulk Rolls, NDC: 55515-014-00. because of Subpotent Drug: Flurandrenolide is subpotent.
Report Card: FDA Earns a Solid